This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Avi Kapoor 1 month ago
MarketsTrading IdeasPre-Market OutlookNewsAnalyst RatingsInitiation
Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- B of A Securities analyst Vivek Arya initiated coverage on IONQ Inc (NYSE:IONQ) with a Buy rating and announced a price target of $60. IonQ closed at $45.48 on Friday. See how other analysts view this stock.
- Cantor Fitzgerald analyst Steve Seedhouse initiated coverage on Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) with an Overweight rating and announced a price target of $8. Lexicon Pharmaceuticals shares closed at $1.80 on Friday. See how other analysts view this stock.
- Evercore ISI Group analyst Alexander Virgo initiated coverage on Fortive Corp (NYSE:FTV) with an In-Line rating and announced a price target of $60. Fortive closed at $56.09 on Friday. See how other analysts view this stock.
- Seaport Global analyst Jeff Cantwell initiated coverage on Jack Henry & Associates Inc (NASDAQ:JKHY) with a Buy rating and announced a price target of $193. Jack Henry & Associates shares closed at $147.79 on Friday. See how other analysts view this stock.
- Argus Research analyst John Eade initiated coverage on 10X Genomics Inc (NASDAQ:TXG) with a Buy rating and announced a price target of $110. 10x Genomics closed at $85.71 on Friday. See how other analysts view this stock.
Considering buying LXRX stock? Here’s what analysts think:
Photo via Shutterstock